UNSPSC 51272707: Methionine methyl ester

This classification denotes a dietary amino acid with the molecular formula C6H13NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BN630929UL, chemically known as (+)-l-methionine methyl ester, but more generally known as methionine methyl ester, which bears US NIH Compound Identifier 64684. European Medicines Agency schedules methionine methyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08850MIG.

Most nations, for tariff purposes, schedule methionine methyl ester under HS 29304010. SMILES: COC(=O)[C@H](CCSC)N.

UNSPSC 51272707 Methionine methyl ester is a Commodity code, but the recent state and local procurement activity posted under it reflects pharmaceutical procurement broadly—including naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs—rather than methionine methyl ester specifically. The code does not show focused activity aligned with its nominal chemical scope. State and local buyers under this taxonomy include county health departments, state HHS commissions, and multistate cooperative purchasing alliances supporting community health, pharmacy benefit, and emergency response initiatives.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted an RFI (HHS0017013, issued April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting between the state and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and certify compliance with cGMP and the Drug Supply Chain Security Act. The mismatch between the code's chemical specificity and the pharmaceutical-procurement breadth of recent activity suggests either miscoding at source or a code assignment that does not align with actual procurement use.